We have recently produced a novel humanized mAb (Hersintuzumab) which displays superior tumor inhibitory activity in combination with Trastuzumab as compared to the combination of Pertuzumab and Trastuzumab (Amiri et al., 2018).The same principle may be applicable for HER3 specific mAbs. This evidence concerns the gene ERBB3 and neoplasm.